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Summary.-In a controlled clinical study ("clinical trial") to compare 2 or more
treatments for a disease, an objective method of allocating patients to treatment
groups is needed. Various existing methods of allocation are described, including
those which take account of patients' pre-treatment characteristics.
IT IS OFTEN DESIRED to compare 2 or
more methods oftreatment for a particular
disease, where it is not known in advance
which treatment is the more effective.
Whether one treatment is new, or whether
all are established in practice, the best
comparison will be obtained by under-
taking a prospective, controlled study
(Hill, 1977). One question which arises
early in the planning of such a study is
how the patients are to be allocated to the
different treatment groups, in order to
obtain a meaningful comparison.
There are 2 main considerations when
deciding on the method of allocation. The
first is that the patients should be allocated
to the treatment groups in such a way that
scientifically valid conclusions can be
drawn at the end of the study, giving the
maximum amount of information on the
relative merits ofthe different treatments.
Statistical matters will enter into this. The
second consideration is that the allocation
procedure must be feasible in practice as
well as in theory. In general, patients will
enter the study one by one, and the
treatment for each patient will need to be
known soon after entry. Thus the alloca-
tion procedure must not be too complex
or time-consuming. Indeed a complicated
scheme could be counter-productive, in
that it might deter busy clinicians from
entering patients into the study.
Here we describe schemes which both
provide "good" allocations, and have been
found to be convenient in practice. No
statistical or computational expertise is
required for any of the procedures. The
analysis of the results of a study is not
considered here, as this has been well
documented elsewhere (Armitage, 1971;
Peto et al., 1976, 1977).
Allocation schemes: the need for randomt-
ization
The essential aim of any method of
treatment allocation in a clinical study
is to allow an efficient statistical compari-
son of the merits of the treatments to be
made at the end of the investigation. We
shall discuss the allocation schemes which
are most reliable in achieving this end. For
the most part we shall restrict our dis-
cussion to a study comparing 2 treat-
ments, A and B (say), where approxi-
mately equal numbers of patients are to
receive each treatment. Not all studies
fall into this category. Some aim to
compare more than two treatments (e.g.
the Medical Research Council investiga-
tions in the treatment of rectal cancer
(1974)) and in some studies it is preferable
to have more patients in one treatment
group than in another (Peto et al., 1976).
Similar considerations to those discusse(d
here would apply in such cases, although
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the methods would require some simple
modifications.
We assume throughout that patients
enter the study one by one, generally
over some period of time.
Subjective and deterministicprocedures.-
Clinicians are used to choosing themselves
the treatment which they consider is best
for their patient. Such a decision will be
based on their knowledge of the efficacy
ofthe treatment, and the possibility ofany
unacceptable side effects. The tacit
assumption behind a clinical study, how-
ever, is that it is not known initially
which is the "better" of the 2 treatments
for a patient. (If there are individual
patients for whom one treatment is pre-
ferred, they are not included in the study.)
Nevertheless it is not uncommon to find
clinicians who, while having some general
preference for one of the treatments, still
decide to take part in an investigation.
They do this because they recognise that
the study will give them an evaluation of
the relative merits of the 2 treatments
which is more reliable than the informa-
tion they already possess.
Since a clinician may have a preference
for one treatment, it would not be wise to
allow him to allocate the treatment by his
own choice to each patient. This is
because he might, for example, either
consciously or unconsciously give the
treatment he preferred to those patients
with a better prognosis, thus hoping to
ensure a good result for this treatment.
Even if this is unlikely to happen, it is
best to exclude the possibility completely,
so that there can be no doubt in the
matter at the end of the investigation.
We therefore require an allocation
procedure which is not subjective, that is,
not dependent on anyone's personal decis-
ion. One such method is that of "alterna-
tion". We give treatment A to the first
patient who enters the study, B to the
second, A to the third, and so on. This
method has the advantage of being
extremely simple to carry out. The very
simplicity of the scheme raises a problem,
however, since the clinician will be aware
of the treatment which is to be allocated
to the next patient. He will therefore be in
a position to select the patient whom he
considers most suitable for that treatment,
so that the type of concealed difference
mentioned above could possibly arise.
The alternation method is an example
of a "deterministic" procedure. Othersuch
procedures are allocation according to the
last digit of the hospital number, first
letter ofsurname, or month ofbirth. These
all allow the possibility of concealed
differences between the treatment groups,
because the treatment allocation can be
determined before the decision to enter
the patient to the study has been made.
In addition, there may well be other
forms of bias. For example, there could be
a difference in racial characteristics be-
tween the groups, if the first letter of
surname is used.
Simple and restricted randomization.
To avoid the possibility of prediction of
the next allocation, a random element is
usually introduced into the procedure. The
simplest form of randomization is equiva-
lent to tossing a coin, and allocating A or
B depending on whether the coin comes
down "heads" or "tails". In practice a
list of random numbers produced by a
computer is used to give a random
sequence of As and Bs (Armitage, 1971).
SSuch a sequence is shown in Table I.
In the long run, sequences based on
random numbers will lead to approxi-
mately equal numbers of As and Bs, but
by chance there may sometimes be a large
imbalance. From the statistical point of
view it is not essential to have exactly
equal numbers on the two treatments, but
a more efficient comparison will generally
be obtained if the numbers are as close as
possible (see Appendix). Although serious
losses in efficiency are unlikely to occur
from a chance imbalance in numbers, it
would appear sensible to rule out the
possibility.
A modification of the above method is
known as "restricted randomization". In
this method the numbers of patients
allocated to each treatment are forced to
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be e(ual after every 6 patients, say, have
entered the study. (The "balancing num-
ber" 6 is at the discretion ofthe organizer.)
Thus if 3 of the first 4 patients have been
allocated treatment A, the next 2 patients
will necessarily be allocated B, so that
after 6 patients have been entered there
will be 3 in each treatment group. The
same system is used for the next 6
patients, and so on, until the entry of
patients is completed. Table I is, in fact, a
restricted randomization list with balanc-
ing number 8.
So that it is more difficult for the
investigator controlling entry of patients
to predict the next allocation, he should
remain unaware of the balancing numnber.
Other devices can be introduced to
prevent the pattern being detected as the
study progresses. One such is to split one of
the blocks of 6 (or whatever number is
used) into two parts, and to insert one
part at another point in the sequence.
A method of producing a restricted
randomization list has been described by
Peto et al. (1976). For a balancing number
6, each ofthe 20 possible sequences of 3 As
and 3 Bs is associated with a different set
of 2-digit numbers (e.g. AAABBB can be
associated with the numbers 00 to 04,
AABABB with 05 to 09, and so on). Pairs
of digits are then read from a list of
random numbers, and the corresponding
sequences are written down in order.
Whatever method is used to produce the
list of As and Bs, the final sequence must
not, of course, be available to the investi-
gator entering patients. If he knows in
advance what the allocation for a patient
will be, the purpose ofthe randomization is
lost. One procedure is then to make out a
card for each allocation. The patient serial
number and allocated treatment are
written on the card, and the card is sealed
in an envelope bearing only the serial
number. The envelopes are kept by the
clinician in a pack in order of serial
number, and the allocation is made by
opening the next envelope in the sequence
as each patient enters the study.
Another possibility is for anindependent
person to keep the list ofAs and Bs, and to
tell the clinician the allocation only after
he has entered a patient. This means that
the procedure can be seen to be completely
objective. A further advantage of this
method in a multicentre study, where the
treatment allocation is obtained by tele-
phoning one main office, is that a central
record can be kept of the patients who
have been entered. It is then possible to
check at a later date that no patient has
been lost to the study.
The use ofprognostic information
Before a patient starts treatment, we
often have certain information which we
know or suspect will be related to prog-
nosis. For example, the patient's age, or
the stage which the disease has reached
before treatment starts may affect the
prognosis. We shall refer to such pre-
treatment items of information as "prog-
nostic variables". In a multicentre study
we may wish to see if the results vary
between centres, and then "centre" is
considered to be a prognostic variable.
When analysing the results of a study,
we can use these variables in 3 ways.
First we may see if there is any evidence
that a variable does relate to prognosis.
This may shed light on the disease process
or on the mode ofaction ofthe treatments.
It may also be valuable to the clinician
in the future choice of treatment policy,
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and may be socially useful if it permits a
more accurate prediction of the outcome
for a patient. Secondly we may allow for
any imbalance in the distribution of the
important variables across the treatment
groups, in our comparison of the treat-
ments. Thirdly we may be able to identify
subgroups of patients, in terms of the
prognostic variables, who respond to
treatment differently from the remainder.
This last possibilitv requires a larger
number of patients in the study than the
other 2.
To achieve these aims it is desirable to
have similar numbers of patients who are
alike, in terms ofthe prognostic variables,
receiving the 2 treatments. For example,
if older patients might respond differently
from younger patients, we would prefer
to have halfofour older patients receiving
Treatment A, and half Treatment B. We
could then see if, for older patients as
distinct from younger, there was some
difference in response to treatment. Simi-
larly, if "centre" is a prognostic variable,
we shall wish to have similar numbers of
patients in a centre receiving each treat-
ment.
Powerful methods of statistical analysis
are available to allow for the effects of
prognostic factors in the main treatment
comparison, and these compensate to a
large extent for an unequal treatment
allocation (Armitage and Gehan, 1974;
Cox, 1972). However, we shall make best
use of the resources if we aim to have
equal numbers for the variables which we
suspect to be related to prognosis. Usually,
loss of precision in the main comparison
by omitting to balance for a prognostic
factor will be small (see Appendix).
Nevertheless, where important prognostic
variables are known to exist, it would
seem sensible to opt for the extra precision
obtained from balanced numbers, if bal-
ance can be achieved simply. It is likely
that the gain in precision in the main
treatment comparison will be of most
importance in studies with <100 patients,
where several important prognostic factors
exist. Balanced numbers may also be
valuable when examining interactions
between treatment and prognostic varia-
bles, even for larger studies.
We then wish to have an allocation
scheme which takes account of each
patient's values ofthe prognostic variables
before allocating treatment. In such a
scheme, it will generally only be possible
to include prognostic variables which are
readily available at the time the patient
enters the study, since waiting for other
assessments to be made could delay treat-
ment. Such information as age, sex and
diagnosis can in general be quickly
obtained, but it should be remembered
that details such as laboratory results
may not be immediately available. It may
be better not to attempt to balance for a
variable, rather than have patients lost to
the study because there is no time to find
the necessary information.
Stratifed randomnization.-When the
prognostic variables to be used in alloca-
tion have been chosen, one method which
can sometimes be used is to have a
separate restricted randomization list for
each "stratum" defined by the variables.
For example, suppose that there is one
prognostic variable, age, with two "levels"
(i.e. possible categories): over 65 and 65 or
under. A separate randomization sequence
is employed for each prognostic stratum,
namely one sequence for the patients over
65, andoneforthose 65 orunder (TableII).
This method of allocation is known as
"stratified randomization". As with simple






























* E signifies over 65
t Y signifies 65 or under.
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can be implemented by using sealed
envelopes or through an independent
person holding the allocation sequences.
Suppose now, that a further prognostic
variable, clinical stage, is to be included,
having 2 levels: early stage, and late
stage. The number of prognostic strata
increases from 2 to 4, namely (i) over 65,
early; (ii) over 65, late; (iii) 65 or under,
early, and (iv) 65 or under, late. The
number ofseparate randomization sequen-
ces is, therefore, also increased to 4.
As the number of prognostic variables
increases, and especially if those variables
have more than 2 levels, the total
number of prognostic strata soon in-
creases to an unmanageable size. For
example, a study with 4 prognostic
variables which have 2, 2, 3 and 4 levels
has a total of 2x2x3x4 48 strata. If
only 100 patients are to be entered, the
numbers ofpatients in many strata will be
too small for the balancing of treatment
numbers, so that the method will not
operate efficiently.
A new method: minimiization. A numn-
ber of procedures have been suggested to
cope with this problem, but they are often
too complex to be practical. One method,
sometimes known as "minimization", has
been developed recently (Taves, 1]974;
Pocock and Simon, 1975; Freedman and
W;\hite, 1 976). It overcomes the difficulties
of large numnbers of strata by allowing the
investigator to choose to balance the
treatment groups in a less complete way
than that attempted in stratified random-
ization. Stratified randomization aims to
obtain equal numbers on each treatment
for every possible combination of the
prognostic variables, whereas the mini-
mization method restricts its aim to
equalizing treatment numbers at the
different levels of each variable taken
separately. In special cases where 2
prognostic variables interact, so that it is
their combination which is of interest, the
minimization method can be adapted to
balance numbers among all combinations
of that pair of variables, as well as among
the remaining variables separately. Mini-
mization has been shown to be superior to
both simple and stratified randomization
in producing balance for the separate prog-
nostic variables, for the size of study most
often undertaken. Itisparticularlysuperior
when the number of strata is large in
comparison with the number of patients
(Pocock and Simon, 1975).
We shall describe a simple version ofthe
method, and show how it can be made
more sophisticated if necessary. The
general method is quite complex, and
often needs a small computer for its
implementation, but the simplified version
needs only a few hand additions of
numbers.
The method aims to achieve a final
distribution of treatments which is bal-
anced with respect to each separate prog-
nostic variable. It does this by choosing
the treatment for each new patient
entering the study in such a way that the
'treatment imbalance" after admitting
that patient is as small as possible.
For example, suppose that age is a
prognostic variable, with the 2 levels
"over 65" and "65 or under", and a new
patient over 65 years of age is to be
assigned a treatment. If there are already,
for example 12 patients over 65 receiving
Treatment A and 10 receiving B, the
resulting imbalance if we assign this
patient to A can be described by 13-10
3. Similarly ifwe allocate B, the imbalance
calculated in this wayis 122 11 1. Ifthere
is just this one prognostic variable, we
choose to allocate B, because this gives the
lesser imbalance.
If there are other prognostic variables,
we calculate similar measures for each one.
Then the total imbalance which would
result from allocating Treatment A is
described by the sum over the prognostic
variables of the imbalances corresponding
to A, and that for B by the sum of the
imbalances corresponding to B. We then
compare the 2 total values, and choose
to allocate that treatment which gives the
smaller treatment imbalance.
Implementation of the method. Fortu-
nately we do not need to do all the cal-
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culations detailed above at every stage,
because they can be condensed to a simple
procedure. Surprisingly, it turns out in
practice to be easier to use as a measure of
imbalance not the difference between the
numbers in the treatment groups, were a
particular treatment to be assigned, but
their statistical vcariance. (In the case of
2 treatments this is equivalent to using
the square ofthe difference.) It may not be
immediately obvious that the method we
describe bears any relation to using the
variance measure to minimize imbalance,
but it is in fact equivalent (Freedman
and White, 1976). We shall describe the
method for a study with a general (un-
specified) number m of prognostic varia-
bles.
Suppose that a new patient enters the
studv, and that his (or her) levels ofthe mn
prognostic variables are rl, r2, etc., up to
rm. For illustration, there might be 4
prognostic variables (m=4) in a study of
cancer therapy:


























Then if the new patient is aged 58, male,
stage T3 and with a poorly differentiated
tumour, his levels of the 4 variables are 1,
1, 3 and 3 respectively (i.e. ri 1, r2=1,
r3=3 and r4=3).
In order to make the allocation we look
at the nunmbers ofpatients, at each ofthese
particular levels ri, r2, . ., rm ofthe varia-
bles, who have been allocated A and B so
far. (The numbers at the other levels are
ignored.) Suppose that the numbers of
patients at Level ri of Variable 1 already
allocated to A and to B are a, and b,
respectively. For Level r2 of Variable 2,
suppose that the corresponding numbers
are a2 and b2, and so on up to Level rm of
variable m, where the numbers already
allocated to A and B are am and bm
respectively. The method is to form the
2 sums al+a2+ . . . +am and bl+b2+
... bm and to compare them to see which
is the lower. We choose Treatment A for
the new patient if the first sum is lower,
Treatment B if the second sum is lower.
If the sums are identical, we can choose
between A and B using a prepared random
sequence of allocations. This sequence can
be similar to that described in the section
on simple randomization, with each allo-
cation being deleted when it has been
used to resolve a tie. An alternative pro-
cedure, which can be useful when a
sophisticated version of the method is
employed, is detailed below.
Table III shows the calculations at a
























treatments, where the prognostic variables
and new patient are as described earlier
in this section. The totals for A and B are
31 and 29 respectively, so we allocate B.
It may be seen that this allocation
decreases the imbalance for these levels of
the variables age and stage, but increases
it for sex and grade. The total imbalance,
as defined, is however less by allocating B
than by allocating A.
To operate the procedure conveniently,
a simple way of storing information on
patients already in the study is to have a
2. Sex
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STAGE Level 3: T3
Treatment A Treatment B
1. 015* 6. 1. 007 6. 064
2. 036 7. 2. 019 7.
3. 050 8. 3. 035 8.
4. 061 9. 4. 049 9.
5. 10. 5. 056 10.
* Patient reference number.
FIG. Sample index card.
set of index cards, with one card for each
level of each prognostic variable (Fig.).
The cards may be indexed by factor, for
ease ofhandling. On each card we enter the
studyreference numbers ofpatients atthat
level ofthe variable, in columns according
to the treatment allocated. When a new
patient enters, the cards corresponding to
the patient's levels of the variables are
drawn from the set. The numbers ai and bi
can easily be read from the cards, and the
sums formed. Once the treatment is
allocated, the new patient's reference
number is entered on these cards in the
appropriate columns, and the cards are
replaced.
Sophi8tications ofthe method: (a) random
element.-One objection which might be
made is that the method is largely
deterministic, and so in principle an
investigator could work out in advance
what a patient's treatment would be.
This problem does not arise with multi-
centre studies, where the information
about total patient entry is only available
to the central coordinator. None of the
clinicians entering patients then has
sufficient information to predict the next
allocation.
Where a random element i8 needed, this
can be introduced quite simply. We need
not automatically choose the treatment
which leads to the lower sum, but can
instead choose according to a scheme
which gives some chance of choosing the
other treatment. Of course we shall still
need to maintain a higher chance of
choosing the treatment which leads to the
lower imbalance, or the main property of
the method (balance) is lost.
If there are 2 treatments, a simple
way of making the procedure non-deter-
ministic is to add a (positive or negative)
"random" number to the total for A,
before comparing it with the total for B.
An appropriate list of random numbers is
prepared at the beginning of the study,
and each number is deleted as it is used.
For instance, the list could consist of the
nunmbers -4, -3, -2, -1, 0, 1, 2, 3, 4,
each occurring equally often in a random
fashion. If for example the total for A is 2
more than the total for B, adding the
random number will lead to B being
chosen 6/9 ofthe time (when - 1, 0, 1, 2, 3,
or 4 appear), A being chosen 2/9 of the
time (when -4 or -3 appear), and a tie
occurring 1 time in 9 (when -2 appears).
The possibility of a tie can be avoided
altogether when this method is used, as
the values + 1 and - can also be added
to the total for A (each used equally often,
at random). Thus the random list will
consist of the numbers 41, 31, -2k,
-12 1 1 11 21, 31 and 41. In the 2 ' 2 ' f 2' 2' 22 example above, B will then be chosen with
probability 7/10, and A with probability
3/10. If the total for A is 4 more than the
total for B, B will be chosen with pro-
bability 9/10, and A with probability only
1/10. Thus as the potential imbalance
becomes larger, the probability ofchoosing
the treatment leading to the lower im-
balance also increases. This preserves the
good balancing properties of the scheme.
Use of the numbers illustrated above
will give a deterministic allocation when-
ever the difference between the totals is
5 or more. This is because addition of the
random number to one total can make no
difference to which total is the lower. A
way of avoiding this is to replace the
values -41 and 4- by -I000 and 1000
respectively. When the difference between
the totals is 4 or more, there will then be
always a 1/10 chance of not choosing the
treatmentleadingtothesmallerimbalance.
The introduction ofthe random element
has certain disadvantages, in that the pro-
cedure then takes longer to carry out, and
there is a greater possibility of imbalance
creeping in. Its introduction is often not
necessary.
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(b) 1W'eighting.-The separate values a1,
a Am and b1, . . ., bm may be multiplied
by weighting factors before they are
summed to give the totals. The -weighting
factor for a particular prognostic variable
must be chosen before the start, of the
study by the investigator, according to
how important he considers it is to
achieve balance for that variable. Thus
the more important the variable, the
larger will be the chosen weighting factor.
Inevitably the choice of weights will be
somewhat arbitrary. The method described
above gives a weighting factor of one to
every, variable, thus assigning the same
amount of importance to each.
To avoid carrying out multiplications
every time an allocation is made, a
weighting factor can be incorporated into
the sequence numbering on the index
cards. Thus the numbers 1, 2, 3, . (Fig.)
are replaced by 2, 4, 6 ... ifthe variable has
weight 2. The last number is then read
from the card when making, the allocation.
(c) Randomizinq in ratio k:1.-If it has
been decided that there should be k
times as many patients receiving Treat-
ment A as receiving Treatment B, the
necessary adjustment will be to multiply
the total for B by ki before comparing it
with the total for A.
(d) More than two treatments-.The
method extends naturally to any number
of treatments. For 3 treatments, we
compare 3 totals formed as above, and
choose that treatment corresponding to the
lowest suLm.
Choice of method
In the previous sections, each new
method has been presented as a refine-
ment of the one before it. However, this is
not meant to imply that the most complex
method is necessarily the best one to use in
every situation.
We recommend that one of 3 methods
be used: "restricted" randomization, "stra-
tified" randomization, or "minimization".
The choice between the methods for anv
study will depend on such factors as the
number of patients to be entered, the
importance and number of ally known
prognostic variables, the ease with which
the prognostic information can be obtained
at the time ofallocation, whether there are
one or many centres involved, and the
organizational set-up for treatment allo-
cation. The account given in the preceding
sections aims to give the background
against which an informed choice can be
made.
APPENDIX
Suppose that w%ith a current method of
treatment, only 500 of patients w-ith a
certain disease live longer than 5 years. W\e
wish to see if there is a significant (P_0 05)
difference in survival when a new treatment is
used, and are interested in an improvement to
(say) 80%.
If we enter 100 patients into our study, and
allocate 50 (at random) to each treatment, the
statistical power" of the study to detect a
30% change is about 89/. This meansthat we
have 89 chances in 100 of showing signifi-
cance, ifthe new treatment improves survival
to 800/o* Ifwe have 66 receiving one treatment
and 34 the other, the power decreases to 86%,
which is approximately equivalent to the
powerproduced byincluding 10 fewerpatients
in the study, with equal allocation. If the
allocation is 75:25 the power is 78%, equiva-
lent to having about 25 fewer patients.
Now suppose that there is one prognostic
variable, with two levels, and that the survival
on the current treatment is 50% at the first
level and 20% at the second. If there are 50
patients at each level, and the newv treatment
actually improves survival by 3000 (at each
level), equal allocation within the levels will
give a poNwer of almost 90%/' to detect a
change ofthis size. Ifwe have equal allocation
overall, but do not control the allocation at
each level, we could find that the totals in the
treatment groups are 30:20 at one level, and
20:30 at the other. This situation would lead
to a slightly decreased power, of880. A 35: 15
allocation w%ould reduce the power to 84%.
We wish to thank Dr Ian Sutherlancd ancl Richar(d
Peto for helpful comments on the manuscript. The
proce(lulre for introduicing a random element into the
method was suggeste(l by Richar(d Peto.
REFERENCES
ARMiITAGE, P. (1971) Statistical Mllethods it? Mledical
Research. Oxford: Blackwell.ALLOCATION OF PATIENTS IN CLINICAL STUDY 857
ARMITAGE, P. & GEHAN, E. A. (1974) Statistical
Methods for the Identification and Use ofPrognos-
tic Factors. Int. J. Cancer, 13, 16.
Cox, D. R. (1972) Regression Models and Life Tables.
J. R. Stati8t. Soc. B., 34, 187.
FREEDMAN, L. S. & WHITE, S. J. (1976) On the Use
of Pocock and Simon's Method for Balancing
Treatment Numbers over Prognostic Factors
in the Controlled Clinical Trial. Biometrics, 32,
691.
HILL, A. BRADFORD (1977) A Short Textbook of
Medical Statistics. London: Hodder & Stough-
ton.
MEDICAL RESEARCH COUNCIL (1974) Protocol for
Trial in Pre-Operative Radiotherapy for Rectal
Cancer. MRC 74/1033.
PETO, R., PIKE, M. C., ARMITAGE, P., BRESLOW,
N. E., Cox, D. R., HOWARD, S. V., MANTEL, N.,
MCPHERSON, K., PETO, J. & SMITH, P. G. (1976)
Design and Analysis of Randomized Clinical
Trials Requiring Prolonged Observation of Each
Patient. I. Introduction and Design. Br. J. Cancer,
34, 585.
PETO, R., PIKE, M. C., ARMITAGE, P., BRESLOW,
N. E., Cox, D. R., HOWARD, S. V., MANTEL. N.,
MCPHERSON, K., PETO, J. & SMITH, P. G. (1977)
Design and Analysis of Randomized Clinical
Trials Requiring Prolonged Observation of Each
Patient. II. Analysis and Examples. Br. J.
Cancer, 35, 1.
POCOCK, S. J. & SIMON, R. (1975) Sequential Treat-
ment Assignment with Balancing for Prognostic
Factors in the Controlled Clinical Trial. Bio-
metric8, 31, 103.
TAVES, D. R. (1974) Minimization: A new method of
assigning patients to treatment and control
groups. Clin. Pharmac. Therapeut. 15, 443.